OSAKA, Japan, May 9, 2025

日本大阪，2025年5月9日

- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced that it has entered into a joint research agreement with CILCARE SAS (Headquarters: Montpellier, France; CEO: Celia BELLINE; hereinafter 'Cilcare') for the creation of a new drug pipeline for hearing loss. .

－盐野义制药株式会社（总公司：日本大阪；首席执行官：手代木功博士；以下简称“盐野义”）宣布已与CILCARE SAS（总部：法国蒙彼利埃；首席执行官：塞莉亚·贝利内；以下简称“Cilcare”）达成联合研究协议，以建立针对听力损失的新药研发管线。

Hearing loss is a major global health issue affecting around 5% of the world’s population, had hearing loss disability, accounting for 432 million adults & 34 million children, thus, influencing their quality of life. Its incidence is rapidly increasing, with predictions that, by 2050, a quarter of the global population will experience varying degrees of hearing deficiency.

听力损失是一个主要的全球健康问题，影响着全球约5%的人口，其中4.32亿成年人和3400万儿童存在听力残疾，从而影响他们的生活质量。其发病率正在迅速上升，预计到2050年，全球四分之一的人口将经历不同程度的听力缺陷。

1,2

1,2

. Furthermore, hearing loss is a risk factor for the onset of dementia, and it has been reported that eliminating hearing loss can reduce the risk of developing dementia

此外，听力损失是痴呆症发作的一个风险因素，据报道，消除听力损失可以降低患痴呆症的风险。

3

3

. However, at present, the detailed pathological mechanisms are unknown, and there are no effective treatments available, making it a disease with high unmet needs

然而，目前其详细的病理机制尚不清楚，也没有有效的治疗方法，因此它是一种具有高度未满足需求的疾病。

4,5

4，5

. Among these, Cilcare is one of the world's leading companies coupling advanced non-clinical research technology with clinical know-how, and, in an option agreement with Shionogi, is advancing the development of drug candidates for hearing loss (CIL001, CIL003)

其中，Cilcare 是全球领先的公司将先进的非临床研究技术与临床知识相结合的公司之一，并且在与盐野义制药的期权协议下，正在推进针对听力损失的候选药物（CIL001、CIL003）的开发。

6,7

6,7

.

。

In this collaborative research, we will integrate Shionogi's drug discovery expertise with Cilcare's specialized knowledge in hearing loss to develop innovative treatments targeting novel mechanisms. Additionally, by adopting Cilcare's non-clinical evaluation technology, we can expedite our collaborative research and advance product development from an early stage.

在这项合作研究中，我们将整合盐野义的药物发现专业知识与Cilcare在听力损失方面的专业知识，开发针对新机制的创新治疗方法。此外，通过采用Cilcare的非临床评估技术，我们可以加快合作研究，并从早期阶段推动产品开发。

Leveraging clinical trial data from Cilcare will enhance our translational research capabilities in this field, contributing to the generation of an ongoing pipeline of future development candidates..

利用Cilcare的临床试验数据将增强我们在这一领域的转化研究能力，有助于生成未来开发候选者的持续管道。

Shionogi has identified “Contributing to a Healthy and Prosperous Life” as a materiality to address. We are committed to creating a society where everyone can lead a longer and more vibrant life, staying true to themselves. Shionogi continues to strive to deliver innovative treatments for diseases with high unmet medical needs, including hearing loss, to patients as quickly as possible..

盐野义制药将“为健康和富足的生活做贡献”确定为关键议题。我们致力于打造一个让每个人都能更长久、更有活力地保持真我的社会。盐野义将继续努力，尽快为包括听力损失在内的、具有高度未满足医疗需求的疾病提供创新疗法。

Reference:

参考：

1: Hearing Loss Disease Treatment Market Size & Growth to 2028　(kbvresearch.com)

1: 听力损失疾病治疗市场规模与增长至2028年 (kbvresearch.com)

2:

2:

Haile LM, Kamenov K, Briant PS, Orji AU, Steinmetz JD, Abdoli A, et al. Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet. 2021.

海尔 LM，卡梅诺夫 K，布里昂特 PS，奥尔吉 AU，斯坦梅茨 ID，阿卜杜利 A，等。1990年至2019年听力损失患病率与伤残生存年数：2019年全球疾病负担研究的结果。《柳叶刀》。2021年。

3:

3:

Livingston G. et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.

利文斯顿·G. 等。《柳叶刀》常设委员会2024年报告：痴呆症的预防、干预与护理。

Lancet.

柳叶刀。

2024; 404: 572-628.

2024；404：572-628。

4:

4:

McDaid D et al. Estimating the global costs of hearing loss

麦克戴德 D 等。估算全球听力损失的成本

Int J Audiol.

国际听力学杂志。

2021; 60: 162-170.

2021；60：162-170。

5: Shearer AE, Smith RJH. Genetic hearing loss. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

5: Shearer AE，Smith RJH。遗传性听力损失。In: StatPearls [互联网]. 佛罗里达州金银岛：StatPearls 出版社；2024年。

6:

6:

Option Agreement with Cilcare for Development Compounds Addressing Hearing Loss｜ SHIONOGI

与Cilcare就治疗听力损失的开发化合物达成期权协议｜盐野义制药

7:

7:

Shionogi R&D Day 2024

盐野义研发日 2024

About Cilcare

关于Cilcare

Cilcare is a biotechnology company specializing in auditory science, developing cutting-edge solutions for the characterization, diagnosis, and treatment of hearing impairments and related disorders. Since its founding in 2014, Cilcare has been addressing these global challenges by combining an advanced research and development platform, a promising portfolio of drug candidates, and the use of artificial intelligence and machine learning to characterize various forms of hearing impairments.

Cilcare是一家专注于听觉科学的生物技术公司，致力于开发用于听力障碍及相关疾病特征分析、诊断和治疗的前沿解决方案。自2014年成立以来，Cilcare通过结合先进的研发平台、前景广阔的候选药物组合，以及利用人工智能和机器学习来表征各种形式的听力障碍，应对这些全球性挑战。

Over the past decade, Cilcare has provided its technology to industry leaders and researchers in Europe, America, and Asia, accelerating the development of drugs, gene and cell therapies, and medical devices for hearing impairments..

过去十年，Cilcare 向欧美和亚洲的行业领导者和研究人员提供了其技术，加速了治疗听力障碍的药物、基因和细胞疗法以及医疗器械的开发。

For more information, please visit

欲了解更多信息，请访问

Cilcare’s website

Cilcare官网

.

。

About CIL001

关于CIL001

CIL001 is a novel hearing loss treatment candidate with auditory nerve protection properties, introduced by Cilcare in 2020. In previous non-clinical trials, CIL001 has been shown to improve the amplitude of the first wave of auditory brainstem response (ABR) and promote the reconnection of cochlear synapses that connect inner ear sensory cells to the auditory nerve, thereby improving hearing loss.

CIL001是由Cilcare于2020年推出的一种具有听神经保护特性的新型听力损失治疗候选药物。在之前的非临床试验中，CIL001已被证明可以改善听性脑干反应（ABR）第一波的振幅，并促进连接内耳感觉细胞与听神经的耳蜗突触重新连接，从而改善听力损失。

Shionogi has an option agreement to acquire exclusive licenses for the development, manufacturing, and commercialization of CIL001 worldwide..

盐野义制药公司已签署一项期权协议，可获得CIL001在全球范围内的开发、生产和商业化的独家许可。

About Hearing loss

关于听力损失

Hearing loss is a major global health issue affecting around 0.5 billion people worldwide. The significant surge in its incidence is attributed to the growing global population and an increase in the elderly demographic. If this trend continues, it will result in higher health insurance costs, social isolation, poverty, and a decrease in productivity, leading to substantial losses for society.

听力损失是一个重大的全球健康问题，影响着全球约5亿人。其发病率显著上升的原因是全球人口的增长和老年人口的增加。如果这一趋势持续下去，将会导致健康保险费用上涨、社会孤立、贫困以及生产力下降，给社会带来巨大损失。

One of the challenges with hearing loss is its gradual onset, making it difficult for patients to recognize and leading to low diagnosis rates. It is known to hinder various social activities, including communication with others, and is also considered a risk factor for central nervous system diseases..

听力损失的挑战之一是其渐进性发作，这使得患者很难识别，导致诊断率较低。它会阻碍各种社交活动，包括与他人沟通，并且也被认为是中枢神经系统疾病的危险因素。

About Shionogi

关于盐野义制药

Shionogi strives constantly to supply the best possible medicine (healthcare solutions) to protect the health and wellbeing of the patients we serve, and as a united group. We have identified Contributing to a Healthy and Prosperous Life as a material focus. We are committed to creating a society where everyone can lead a longer, more vibrant life, realizing their goals.

盐野义制药始终致力于为我们服务的患者提供最佳的药物（医疗保健解决方案），以维护他们的健康与福祉，并以团队协作的方式为之努力。我们将“为健康繁荣的生活做出贡献”确定为关键重点。我们承诺创造一个让每个人都能更长寿、更有活力地生活，实现自我目标的社会。

For more information, please visit .

如需更多信息，请访问 。

https://www.shionogi.com/global/en/

https://www.shionogi.com/global/en/